Rigel Announces Availability of REZLIDHIA(TM) (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Stock Information for Rigel Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.